Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP…
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”)…
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription…
Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insightsSAN DIEGO, Jan. 6,…
RAMAT GAN, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December…
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December…
PDAOAI PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE)…
• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera…
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of…